Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (September 2022)
24 slides from Enveric Biosciences's investor presentation, Sep 14, 2022
Slide 1: Investor Presentation September 2022
r | y ENVER IC © treneriecin= BIOSCIENCES INVESTOR PRESENTATION SEPTEMBER 2022
Slide 2: Disclaimer
Disclaimer ‘Ths communications for infrmatonal puposs only ad isnot tended to ad doesnot constitute an fer ose othe solttion ofan offer to by any Scurtiso asoltation of any voto approval. it doesnot constitutes prospects or prospectus equaent document. No offering of secures shal be ade except by me
Slide 3: Investment Highlights
Investment Highlights Enveric Biosciences (NASDAQ: ENVB) feo ©OOB 3 go & Mission: To be the best-in-class psychedelic-inspired drug development company for mental health indications. 2 comprised. ofa fear of experienced CNS drug developers who have successfully led programs from inception to market
Slide 4: Executing with Experience and Passion: Pharma & Bio Leadership
Executing with Experience and Passion: Pharma & Bio Leadership Dr.Kevinteach Vice Presicient Translational & Non= Clinical Sciences Dr. Joseph Tucker Mr. Avani Kanubadal Dr. Bob Dagher Mr. Rob Dickey Dr. Peter Facchini Dr. Rlek Light Chief Executive President & Chief chief Medical officer interim CC
Slide 5: Our Board of Directors
avid Johnton, Former 6&0 of Convate, Sversow the $418 Spout of Ervatee rom Sratal vere Squibb former So oraque Biomedical a oveoper ot ‘round core technologies. George Kegler Me Kegier served {98 VP and interim eroot Matinekroat, suecosstully hegetsted ond executed capital folses, developed stratogi
Slide 6: Our Scientific Advisory Board
Our Scientific Advisory Board Maurizio Fava MD Stephen M. Stahl, Shella Dewitt, Ph.D John Krystal MD Michael Liebowitz MD. Scientific Advisor MD, Ph.D Scientific Advisor Scientific Advisor ‘Scientific Advisor Scientific Advisor
Slide 7: Anxiety — Tremendous Unmet Medical Need
Anxiety — Tremendous Unmet Medical Need CNS Disorders Prevalence Per Million Percent of Adults Ages 18-64 in the General Population Who Meet Diagnostic Criteria for Anxiety abt Disorders in the Past Year and in Their Lifetime Headache anxiety Disorders (] Sleep disorders NN 44.9 Mood disorders [EEE
Slide 8: Anxiety Disorders — Very limited innovation in nearly two decades
Anxiety Disorders — Very limited innovation in nearly two decades + Anxiety disorders are: * Chronic conditions + Last at least 6 months and affect the quality of life. + The most common group of mental health conditions in the Us and worldwide + Last approved drug was Cymbalta (Duloxetine) in 2004
Slide 9: Current Investigational Anxiolytic Programs Targeting Opportunity for Innovation
Current Investigational Anxiolytic Programs Targeting Opportunity for Innovation Incannex Classic Psilocybin Psychedelic Usona Classic LSD Psychedelic VistaGen Fasedienol (Aloradine; 4- Neurosteroid androstadienol) Pfizer (Biohaven) Riluzole sublingual (BHV-0223) Glutamate modulator Fabre-Kramer TGF
Slide 10: Limitations of Current Pharmacologic Treatments
Limitations of Current Pharmacologic Treatments Anxiolytics: 1st Generation Psilocybin + Benzodiazepines (BZD) + Currently under investigation + Selective serotonin reuptake inhibitors (SSRIs) + Challenges with patentability + Serotonin norepinephrine reuptake inhibitors (SNRI) + Anecdotal evidence
Slide 11: Psychedelics: natural & synthetic
Psychedelics: natural & synthetic MOA: SHT-2A agonism Treatment Paradigm: + Psychedelic-assisted psychotherapy Indication: Mood, Anxiety & Addiction disorders Enveric’s Focus Modified prodrugs of psilocin + Enhanced properties over classic psychedelics + Intra-nasal and buccal administration routes
Slide 12: EVM201 Series — Enhanced Drug-Like Properties
EVM201 Series — Enhanced Drug-Like Properties Improved EVM201 Risk/Benefit Profile + Optimized delivery route: can be administered intra- nasal, buccal or intravenous + Wide range of dosing flexibility + Faster access to target (brain): avoids first-pass metabolism through intestine and liver (porta
Slide 13: EVM201 Molecules release psilocin and have unique psychedelic profiles in Animal Model
EVM201 Molecules release psilocin and have unique psychedelic profiles in Animal Model EVM201, at different dose levels and brain exposures, produces a consistent level of 5-HT2AR- mediated Head Twitch Response (HTR) in mice. i z ' Range of Psilocybin-induced HTR é 8 5 : Hy i- 4-H ||}. Multiple dose
Slide 14: EVM201 Series Provides Complete Rescue of Anxiety in Animal Model
EVM201 Series Provides Complete Rescue of Anxiety in Animal Model A Single Dose of EVM201 Demonstrates Complete Rescue of Anxiety in Stressed Animal Model Starting on Day-1 and up to Day-7 post-treatment p<0.c00t ae Day 7 fro Marbles Buried (%) Marbles Buried (96) Control Stress Control Stress Stres
Slide 15: Psychedelics: natural & synthetic
Psychedelics: natural & synthetic MOA: SHT-2A agonism Treatment Paradigm: + Psychedelic-assisted psychotherapy Indication: Mood, Anxiety & Addiction disorders Enveric’s Focus Modified prodrugs of psilocin + Enhanced properties over classic psychedelics + Intra-nasal and buccal administration routes
Slide 16: Psychedelics Treatment Limitations
Psychedelics Treatment Limitations EVM801 Series designed to address limitations and unmet needs Controlled Substances with DEA Scheduling that hinders patient access Risk of abuse Risk of CNS toxicity Risk of inducing psychosis High variability and inconsistency of post-dose experience Negative pos
Slide 17: EVM301 Series
EVM301 Series Towards non-Psychedelic New Chemical Entities + New Chemical Entities + Small molecule with novel properties targeting specific brain receptors and networks to generate new clinical benefit + Minimal-to-no psychedelic experience that removes the need for close intervention of a health
Slide 18: EVM301 Series: Holistic Approach for Treating Target Brain Diseases
EVM301 Series Holistic Approach for Treating Target Brain Diseases + Treatment Paradigm: + Optimized treatment regimen for quick, profound and lasting behavioral changes + Monotherapy and/or adjunctive therapy as Single Administration (SA) with Individualized Repeat Dosing (IRD) for a Precision Medi
Slide 19: EVM201 Screening & Lead Optimization
EVM201 Screening & Lead Optimization Two Separate Series of Differentiated Assets for Mental Health Indications ASSET GROUP INDICATION Discovery | Precunical | pHase1 | pHAsE2 | PHases | YFCOMING | TimeLie Development EVM201 Candidate. 4 2022 serlog Anxiety Disorder [v) Nomination IND Filing 17028 E
Slide 20: IP Estate
IP Estate Three Moats Protecting Castle ENVB Second Moat Inner Moat Outer Moat + 5 years New + Submitted 15+ patent » IP Discovery Chemical Entity applications covering Platform (NCE) and 3 years EVM201 & EVM30I1. New Clinical Study + Psybrary and PsyAl (NCS) Exclusivity from FDA. * Portfolio of 500
Slide 21: Upcoming Milestones
Upcoming Milestones EVM201: Lead Candidate Nomination IND Enabling Studies Initiated FDA Pre-IND Meeting IND Submission First-in-human Study Start EVM301: Target Product Profile Process Completion Psybrary Screening Phase Molecule Design Phase Assay Development Phase In-silico Testing In-vitro Testi
Slide 22: Enveric Biosciences will be the best-in-class psychedelic-inspired drug development company
PE nasdaq :ENVB Enveric Biosciences will be the best-in-class psychedelic-inspired drug development company for mental health indications. Cash and Cash equivalents as of June 2022 * Cash On-hand - $18 million Capital Raises since 2021 * January 2021: $9.5 million * February 2021: $12.1 million Marc
Slide 23: Investment Thesis
Investment Thesis Enveric Biosciences (NASDAQ: ENVB) + We are a team of experienced CNS drug developers who have successfully led programs from inception to market approval. + Focused on creating new drugs for Anxiety, the 2"¢ most prevalent CNS disorder with no new drugs since 2004 * Foundation is
Slide 24: Thank you for your time!
| ENVERIC © wrenernecin Mental Health™ BIOSCIENCES Thank you for your time!
Enveric Biosciences — Investor Presentation (September 2022) on 6ix